Results

Total Results: 1,541 records

Showing results for "months".

41. App-D-Opioid-Chronic-Pain-Surveillance-Report-2 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-2.xlsx
    September 30, 2015 - Pain > 3 months, currently prescribed opioids; excluded cancer and end-of-life treatment A. … B, at 3 months Pain intensity (0 to 100 NRS converted to 0 to 10, mean change from baseline): -1.95 ( … of followup Inclusion: 12 months of continuous opioid prescriptions of at least 50 morphine milligram … in the pre period and up to 33 months in the post period Exclusion: Cancer or sickle cell n=77,697 A … , dose NR, 23.0 months followup C: Control (no opioid), new users (n=18,824), dose NA, 24.4 months followup

42. Treatments for Fecal Incontinence: Current State of the Evidence (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/fecal-incontinence_clinician.pdf
    July 01, 2016 - Incontinence Conclusions Evidence to support any fecal incontinence treatments in adults beyond 3 to 6 months … unapproved by the FDA for fecal incontinence treatment) reduced fecal incontinence severity up to 6 months … ��� Quality of life No significant difference in FIQL score was found between groups at 2 to 3 months … (-2.6 points for dextranomer vs. -2.0 points for sham) and at 6 months (-2.5 points for dextranomer … or 6 months (treated group: 6.0 episode reduction [IQR 0.0–12.5] vs. sham group: 3.0 episode reduction

43. Angina-Heart-Attack-Treatments Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/angina-heart-attack-treatments_executive.pdf
    January 01, 2014 - study (<3 months vs. 6 months vs … no difference; 1 observational study (<3 months vs. 6 months vs … , 6 months vs. 12 months, and 6 months vs. 24 months); 1 observational study found no difference in … evidence due to imprecision: all RCTs (1 month vs. 6 months, 6 months vs. 12 months, and 6 months vs … and 6 months vs. 24 months) Stent thrombosis at 6 months, 1 year, and 2 years SOE = Insufficient

44. App-E-Surv-Report-2-Nonopioid-Pharmacol-Chronic-Pain (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-nonopioid-pharmacol-chronic-pain.xlsx
    May 29, 2025 - 2020 India Head-to-Head Good NPP (DPN) Age, mean: 54.5 Female: 39.5% Race: NR Pain duration: 11.4 months … 64% Black: 16% Multiracial: 10% Asian: 3% Pacific Islander: 1% Race not known: 4% Pain duration: ≥6 months … Egypt Fair Chronic pelvic pain Age, mean: 31.4 Female: 100% Race: NR Pain duration, median: 16.5 months … Age, mean: 30.3 Female: 100% Race: White: 97% Black: 0.3% Asian: 2% Mixed: 0.3% Pain duration: ≥3 months

45. Research White Paper: Standardized Library of Depression Outcome Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/standardized-library-depression-white-paper.pdf
    May 01, 2020 - However, to promote harmonization, the workgroup recommended two timeframes (6 months, 12 months) as … The recommendation to capture patient outcomes at minimum at 4-8 months and 10-14 months remains unchanged … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations

46. Research White Paper: Standardized Library of Depression Outcome Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/standardized-library-depression-white-paper.pdf
    May 01, 2020 - However, to promote harmonization, the workgroup recommended two timeframes (6 months, 12 months) as … The recommendation to capture patient outcomes at minimum at 4-8 months and 10-14 months remains unchanged … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations … Timeframe for measurement: 6 months (+/- 60 days) 12 months (+/- 60 days) In some implementations

47. App-D-Opioid-Chronic-Pain-Surveill-Report-1 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
    September 30, 2015 - Pain > 3 months, currently prescribed opioids; excluded cancer and end-of-life treatment A. … B, at 3 months Pain intensity (0 to 100 NRS converted to 0 to 10, mean change from baseline): -1.95 ( … in the pre period and up to 33 months in the post period Exclusion: Cancer or sickle cell n=77,697 A … : Tramadol, new-users, (n=18,824) dose NR, 22.7 months followup B: Other opioids, new users (n=18661) … , dose NR, 23.0 months followup C: Control (no opioid), new users (n=18,824), dose NA, 24.4 months followup

48. Draft - Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer: Appendix D1 Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypofractionated-radiation-therapy-draft-appendix-d1.xlsx
    January 01, 2024 - Follow-up Assessment Timepoints Indicate all timepoints at which follow-up assessments were completed in months … Exclusion criteria were prostate cancer diagnosis > 6 months before study entry, previous therapy for … after random assignment, and then every 6 months thereafter. … Patients were ineligible if they had history of ADT for 4 months before random assignment, an iPSA of … after the end of therapy, then every 2-3 months for the first year and every 6 months for the next 4

49. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
    February 01, 2015 - , but ranged from 1-3 months to 2-4 months (i.e., all had an upper limit of more than 2 months as distinct … ranging from 4 to 8 months. … 1 to 2 months. … 2 to 4 months. … However, even among the products that took longer to complete (minimum 3 months and up to 8 months),

50. Medical Therapies for Children With Autism Spectrum Disorder—An Update (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-medical-executive-170505.pdf
    May 01, 2017 - – Risperidone and aripiprazole improved challenging behaviors in the short term (<6 months, high … Studies were typically of short duration (<6 months, range 4 days to 24 months), with few studies reporting … ), with effects maintained over the longer term (≥6 months) (Table B). … with 6 months of treatment and in one open label extension with no comparison group with mean 21 months … Data on longer term (≥6 months) results and harms of interventions are lacking.

51. Measuring-Blood-Pressure Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure_executive.pdf
    January 01, 2012 - and a trend at 12 months. … at 24 months with SMBP. … but not at 12 months. … DBP at 24 months in favor of SMBP. … at 24 months with SMBP.

52. Disclosure Policy and Form (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/epc-disclosure-policy-form.pdf
    March 01, 2023 - If an individual's involvement in the project lasts longer than 12 months, the EPC Director (or Lead … or anticipated in the next 12 months). … and anticipated over the next 12 months directly to you, to your institution on your behalf, and to … Look Ahead 12 Months If yes, describe type of relationship and durationYesNo Amount or Value 16. … or anticipated in the next 12 months). 

53. Linking Dental Services to Treatment Outcomes for Diabetes: A Rapid Response Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-outcomes-diabetes-rapid-research.pdf
    November 01, 2024 - This study found no significant changes in HbA1c (-6.41 at 6 months, -3.85 at 12 months), FPG (-11.01 … at 6 months, 0.29 at 12 months), or other inflammatory markers. … at 6 months was lower than at 3 months. … ) • 6 months: −0.38% (95% CI [−0.61, −0.16], p=0.0009) 3 months: 52% 6 months: 46% • Differences … In addition, most studies have a follow-up time of 3 months and/or 6 months.

54. A Prioritized Research Agenda for Using the Harmonized Outcome Measures in the Support Patient-Centered Outcomes Research in Depression (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/prioritized-research-agenda.pdf
    October 01, 2021 - ) - Remission rates (at 6 and 12 months) - Rate of suicide ideation and behavior at 12 months Patient-centered … - Remission rates at 12 months - Rate of suicide ideation and behavior at twelve months Patient-centered … Do response rate at 6 months and remission rate at 12 months vary between patients who are screened … , every 6 months versus every 12 months) differ from those were not according to response rate and remission … and 12 months?

55. Evidence-Summary-CER-209-Noninvasive-Nonpharmacological-Treatment-For-Chronic-Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-209-evidence-summary-non-pharma-chronic-pain.pdf
    June 01, 2018 - ), intermediate term (≥6 to <12 months) and long term (≥12 months). … ), intermediate term (≥6 to <12 months) and long term (≥12 months). … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, slight/small, moderate … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, slight/small, moderate … ; Intermediate-Term: ≥6 to <12 months; Long-Term: ≥12 months Effect Size: none, slight/small, moderate

56. Digestible Carbohydrate Intake and Maternal-Infant Outcomes: Appendix D Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-appendix-d.xlsx
    January 01, 2019 - of age Mean age, months (SD): 4.5 (0.5) vs. 4.5 (0.5) % female: 42% vs. 45% Race/ethnicity: NR Birth … B, 6 months 2941 (525) vs. 2941 (497) 9 months 3472 (498) vs. 3432 (538) Mean, g (SD) A vs. … B, 6 months 87.6 (20.9) vs. 83.1 (16.8) 9 months 113.6 (20.6) vs. 103.4 (18.5), p<0.001 NR NR NR NR … B, 6 months 11.7 (3.0) vs. 13.1 (4.0) 9 months 15.9 (3.6) vs. 21.5 (5.7) NR Mean, g (SD) A vs. … B, 6 months 32.3 (6.0) vs. 33.1 (6.7) 9 months 32.8 (5.4) vs. 33.7 (6.9) NR Latva-Pukkila, 2010 Median

57. The Use of Conjoint Analysis to Elicit Patient Preferences in Selecting Treatment Endpoints (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/mcda-johnson.pdf
    August 27, 2012 - There is a dashed line across 3-months and 10-months with an arrow pointing upward (from 5 months to … 10 months) with the equation: ∆ = +0.84. … There is a dashed line across 3-months and 10-months with an arrow pointing upward (from 5 months to … 10 months) with the equation: ∆ = +0.84.

58. Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/nonopioid-pharm-chronic-pain-protocol.pdf
    February 01, 2019 - ), intermediate-term treatment duration (6 to 12 months), and long-term treatment duration (≥12 months … ), intermediate-term treatment duration (6 to 12 months), and long-term treatment duration (≥12 months … ), intermediate-term treatment duration (6 to 12 months), and long-term treatment duration (≥12 months … ), intermediate-term treatment duration (6 to 12 months), and long-term treatment duration (≥12 months … , 6 to 12 months, and ≥12 months).

59. Draft - Primary Hypofractionated Radiation Therapy for Localized Prostate Cancer: Appendix D2 Tables (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypofractionated-radiation-therapy-draft-appendix-d2.xlsx
    January 01, 2024 - tumors), and 27.3% received treatment for 18 or 36 months (high or very high-risk tumors). … Short-term ADT use of <6 months was allowed. … Short-term ADT use of <6 months was allowed. … and 24 months, respectively. … and 24 months, respectively.

60. Version 2_Risk of Reinfection From SARS-CoV-2 -- An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-2-risk-of-reinfection-from-SARSCoV2_0.pdf
    December 31, 2022 - (range 4–13 months). … Protection remains above 80 percent for at least 7 months. … Median followup time was 8 months (range 4–13 months). … For this estimate, strength of evidence is low for 7-10 months and insufficient for >10 months. … Hansen, 202135 10 months No difference in protection estimate over time (3–6 months of followup 79·